A New Blood Glucose Control Scheme for Unannounced Exercise in Type 1 Diabetic Subjects

The artificial pancreas (AP) system or closed-loop blood glucose (BG) regulation is a technological advancement that aims to relieve diabetic subjects from their current decisionmaking burden while tightening their BG levels. However, large disturbances such as meals and exercise still pose great ch...

Full description

Saved in:
Bibliographic Details
Published inIEEE transactions on control systems technology Vol. 28; no. 2; pp. 593 - 600
Main Authors Beneyto, Aleix, Bertachi, Arthur, Bondia, Jorge, Vehi, Josep
Format Journal Article
LanguageEnglish
Published New York IEEE 01.03.2020
The Institute of Electrical and Electronics Engineers, Inc. (IEEE)
Subjects
Online AccessGet full text
ISSN1063-6536
1558-0865
2374-0159
1558-0865
DOI10.1109/TCST.2018.2878205

Cover

More Information
Summary:The artificial pancreas (AP) system or closed-loop blood glucose (BG) regulation is a technological advancement that aims to relieve diabetic subjects from their current decisionmaking burden while tightening their BG levels. However, large disturbances such as meals and exercise still pose great challenges to a fully closed-loop system. In this paper, the problem of BG regulation with unannounced physical activity for type 1 diabetic subjects is addressed. We use a coordinated control strategy with insulin infusion and extra carbohydrates (CHO) for hypoglycemia avoidance. The insulin algorithm is based on a proportional-derivative controller with insulin feedback and the so-called safety auxiliary feedback element (SAFE) layer, and the algorithm for CHO is based on a predictive, quantified proportional-derivative controller. The UVa/Padua simulator glucose-insulin model is modified to include the effects of physical activity and is used to test the new AP. We consider scenarios where the subject does not announce physical activity and with challenging meals. Then, we analyze the performance and robustness of the combined insulin and CHO recommender system and compare them to the insulin-only controller. The simulation results show that the new AP system is able to mitigate daily hypoglycemia episodes (0.9 versus 0.2, p <; 0.01) and increase the time in range during day (91.5% versus 92.4%, p <; 0.01) without increasing the time above 180 mg/dl (6.3% versus 6.4%, p > 0.05).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1063-6536
1558-0865
2374-0159
1558-0865
DOI:10.1109/TCST.2018.2878205